Validation of high throughput screening assays against three subtypes of Cav3 T-type channels using molecular and pharmacologic approaches

Assay and Drug Development Technologies

Volumn 5, Issue 2, 2007, Pages 191-203

  Xie, Xinmin Simon ^a   Van Deusen, Amy L ^b   Vitko, Iuliia ^b   Babu, Daniella A ^c   Davies, Lucinda A ^b   Huynh, Nhung ^a   Cheng, Holden ^a   Yang, Naibo ^d   Barrett, Paula Q ^b,c   Perez Reyes, Edward ^b,c  

^a SRI INTERNATIONAL   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d MOLECULAR DEVICES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; DYE; MIBEFRADIL; NIFEDIPINE; PIMOZIDE; POTASSIUM CHANNEL; POTASSIUM CHLORIDE;

ARTICLE; ASSAY; CALCIUM CELL LEVEL; CELL LINE; CELL MEMBRANE; CONTROLLED STUDY; DEVICE; EMBRYO; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HYPERPOLARIZATION; MEMBRANE STEADY POTENTIAL; SIGNAL NOISE RATIO; VOLTAGE CLAMP;

ALGORITHMS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; CELL LINE; COLORING AGENTS; DATA INTERPRETATION, STATISTICAL; DRUG EVALUATION, PRECLINICAL; FLUOROMETRY; HUMANS; MIBEFRADIL; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; TEMPERATURE;

EID: 34247611341     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2006.054     Document Type: Article

References (46)

1. Perez-Reyes E: Molecular physiology of low-voltage-activated T-type calcium channels. Physiol Rev 2003;83: 117-161.
2. Llinás RR, Ribary U, Jeanmonod D, Kronberg E, Mitra PP: Thalamocortical dysrhythmia: a neurological and neuropsychiatric syndrome characterized by magnetoencephalography. Proc Natl Acad Sci U S A 1999;96: 15222-15227.
3. 2+ channel-dependent sensitization of a novel subpopulation of rat peripheral nociceptors. J Neurosci 2005;25: 8766-8775.
4. Nelson M, Todorovic S, Perez-Reyes E: The role of T-type calcium channels in epilepsy and pain. Curr Pharm Des 2006;12:2189-2197.
5. v1.2. Circ Res 2006;98:105-110.
6. 2+ channels. Neuron 2001;31:35-45.
7. 2+ channel plays a crucial role in stabilizing sleep. Proc Natl Acad Sci U S A 2005;102:1743-1748.
8. Todorovic SM, Jevtovic-Todorovic V, Meyenburg A, Mennerick S, Perez-Reyes E, Romano C, et al.: Redox modulation of T-type calcium channels in rat peripheral nociceptors. Neuron 2001;31:75-85.
9. Dogrul A, Gardell L, Ossipov M, Tulunay F, Lai J, Porreca F: Reversal of experimental neuropathic pain by T-type calcium channel blockers. Pain 2003;105:159-168.
10. Gibbs JW 3rd, Zhang YF, Ahmed HS, Coulter DA: Anticonvulsant actions of lamotrigine on spontaneous thalamocortical rhythms. Epilepsia 2002;43:342-349.
11. Bourinet E, Alloui A, Monteil A, Barrere C, Couette B, Poirot O, et al.: Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. EMBO J 2005;24:315-324.
12. Choi S, Na HS, Kim J, Lee J, Lee S, Kim D, et al.: Attenuated pain responses in mice lacking Ca3.2 T-type channels. Genes Brain Behav 2006 Aug 29; [Epub ahead of print].
13. v3.3: insights into prepulse facilitation. Biophys J 2002; 83:229-241.
14. Schroeder K, Neagle B, Trezise DJ, Worley J: Ionworks HT: a new high-throughput electrophysiology measurement platform. J Biomol Screen 2003;8:50-64.
15. Trumbull JD, Maslana ES, McKenna DG, Nemcek TA, Niforatos W, Pan JY, et al.: High throughput electrophysiology using a fully automated, multiplexed recording system. Recept Channels 2003;9:19-28.
16. Crunelli V, Toth TI, Cope DW, Blethyn K, Hughes SW: The 'window' T-type calcium current in brain dynamics of different behavioural states. J Physiol (Lond) 2005;562:121-129.
17. Chemin J, Monteil A, Briquaire C, Richard S, Perez-Reyes E, Nargeot J, et al.: Overexpression of T-type calcium channels in HEK-293 cells increases intracellular calcium without affecting cellular proliferation. FEBS Lett 2000; 478:166-172.
18. v3.2 (T-type) channels. Assay Drug Dev Technol 2003;1:637-645.
19. 2+/calmodulin-dependent protein kinase II. J Clin Invest 2006;116: 2403-2412.
20. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4: 67-73.
21. Gomora JC, Daud AN, Weiergräber M, Perez-Reyes E: Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol 2001;60: 1121-1132.
22. + channel. EMBO J 2000;19:2483-2491.
23. Traboulsie A, Chemin J, Chevalier M, Quignard JF, Nargeot J, Lory P: Subunit-specific modulation of T-type calcium channels by zinc. J Physiol 2007;578(Pt 1):159-171.
24. Martin RL, Lee JH, Cribbs LL, Perez-Reyes E, Hanck DA: Mibefradil block of cloned T-type calcium channels. J Pharmacol Exp Ther 2000;295:302-308.
25. 3H] Nitrendipine receptors in skeletal muscle. J Biol Chem 1983; 258:6086-6092.
26. 2+ channels. Jpn J Pharmacol 2001;85:339-350.
27. Serrano JR, Perez-Reyes E, Jones SW: State-dependent inactivation of the α1G T-type calcium channel. J Gen Physiol 1999;114:185-201.
28. Vitko I, Chen Y, Arias JM, Shen Y, Wu XR, Perez-Reyes E: Functional characterization and neuronal modeling of the effects of childhood absence epilepsy variants of CACNA1H, a T-type calcium channel. J Neurosci 2005;25: 4844-4855.
29. + channel, is modulated by multiple neurotransmitters in motoneurons. Neuron 2000;25:399-410.
30. Chen YC, Lu JJ, Pan H, Zhang YH, Wu HS, Xu KM, et al.: Association between genetic variation of CACNA1H and childhood absence epilepsy. Ann Neurol 2003;54: 239-243.
31. 2+ channels: a paradigm for CAE mutations. J Neurosci 2007;27:322-330.
32. Coulter DA, Huguenard JR, Prince DA: Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol 1989;25:582-593.
33. 2+ channel causes a long-lasting modification of neuronal firing mode after status epilepticus. J Neurosci 2002;22:3645-3655.
34. Leresche N, Parri HR, Erdemli G, Guyon A, Turner JP, Williams SR, et al.: On the action of the anti-absence drug ethosuximide in the rat and cat thalamus. J Neurosci 1998; 18:4842-4853.
35. + channels in rat hippocampal neurones. Pflugers Arch 1995;430: 437-146.
36. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol 2003;55:683-689.
37. Tsien RW, Clozel JP, Nargeot, J, eds.: Low Voltage-Activated T-Type Calcium Channels. Adis International Ltd., Chester, UK, 1998.
38. Hayashi K, Ozawa Y, Fujiwara K, Wakino S, Kumagai H, Saruta T: Role of actions of calcium antagonists on efferent arterioles - with special references to glomerular hypertension. Am J Nephrol 2003;23:229-244.
39. 2+ channels with efonidipine decreased plasma aldosterone concentration in healthy volunteers. Hypertens Res 2006;29:493-197.
40. McGivern JG: Targeting N-type and T-type calcium channels for the treatment of pain. Drug Discov Today 2006;11:245-253.
41. Nikonenko I, Bancila M, Bloc A, Muller D, Bijlenga P: Inhibition of T-type calcium channels protects neurons from delayed ischemia-induced damage. Mol Pharmacol 2005; 68:84-89.
42. Todorovic SM, Meyenburg A, Jevtovic-Todorovic V: Mechanical and thermal antinociception in rats following systemic administration of mibefradil, a T-type calcium channel blocker. Brain Res 2002;951:336-340.
43. Flatters SJ, Bennett GJ: Ethosuximide reverses paclitaxel-and vincristine-induced painful peripheral neuropathy. Pain 2004;109:150-161.
44. Barton ME, Eberle EL, Shannon HE: The antihyperalgesic effects of the T-type calcium channel blockers ethosuximide, trimethadione, and mibefradil. Eur J Pharmacol 2005;521:79-85.
45. + channels. Neuroscience 1996;73951-962.
46. 2+ channels by the neuroprotective agent BW619C89 (Sipatrigine). Neuropharmacology 2000;39:1247-1253.